Open Access

P-glycoprotein at the blood-brain barrier: kinetic modeling of 11C-desmethylloperamide in mice using a 18F-FDG μPET scan to determine the input function

  • Lieselotte Moerman1Email author,
  • Dieter De Naeyer2,
  • Paul Boon3 and
  • Filip De Vos1
EJNMMI Research20111:12

DOI: 10.1186/2191-219X-1-12

Received: 23 February 2011

Accepted: 29 July 2011

Published: 29 July 2011



The objective of this study is the implementation of a kinetic model for 11C-desmethylloperamide (11C-dLop) and the determination of a typical parameter for P-glycoprotein (P-gp) functionality in mice. Since arterial blood sampling in mice is difficult, an alternative method to obtain the arterial plasma input curve used in the kinetic model is proposed.


Wild-type (WT) mice (pre-injected with saline or cyclosporine) and P-gp knock-out (KO) mice were injected with 20 MBq of 11C-dLop, and a dynamic μPET scan was initiated. Afterwards, 18.5 MBq of 18F-FDG was injected, and a static μPET scan was started. An arterial input and brain tissue curve was obtained by delineation of an ROI on the left heart ventricle and the brain, respectively based on the 18F-FDG scan.


A comparison between the arterial input curves obtained by the alternative and the blood sampling method showed an acceptable agreement. The one-tissue compartment model gives the best results for the brain. In WT mice, the K 1/k 2 ratio was 0.4 ± 0.1, while in KO mice and cyclosporine-pretreated mice the ratio was much higher (2.0 ± 0.4 and 1.9 ± 0.2, respectively). K 1 can be considered as a pseudo value K 1, representing a combination of passive influx of 11C-desmethylloperamide and a rapid washout by P-glycoprotein, while k 2 corresponds to slow passive efflux out of the brain.


An easy to implement kinetic modeling for imaging P-glycoprotein function is presented in mice without arterial blood sampling. The ratio of K 1/k 2 obtained from a one-tissue compartment model can be considered as a good value for P-glycoprotein functionality.


Multidrug transporters, with P-glycoprotein (P-gp) as most investigated, are a large family of ATP-binding cassette membrane proteins, which appear to have been developed as a mechanism to protect the body from harmful substances [1]. In the blood-brain barrier (BBB), P-gp are responsible for pumping toxic compounds out of the brain, resulting in low concentrations of endogenous and exogenous compounds in the brain. Moreover P-gp overexpression has been observed in brain tissues, obtained after surgery in some epileptic patients [24], and could also play a role in other neurological diseases. Since these studies are invasive, it would be useful to have a noninvasive method to predict if P-gp is upregulated in patients.

P-gp function can be studied in vivo with radiolabelled substrates. Desmethylloperamide is a metabolite of loperamide, a licensed antidiarrheal agent without central nervous system side effects because P-gp excludes it from the brain [5]. 11C-desmethylloperamide (11C-dLop) is believed to be the most promising tracer to evaluate P-gp function in the brain [6]. One of the standard methods to investigate the P-gp function in particular, is the use of P-gp knock-out mice. The combination with P-gp blocking studies will give an unquestionable indication of the P-gp function [7].

The objective of this study is the implementation of a kinetic model for 11C-dLop and the determination of a typical parameter for P-gp functionality in mice. To set up a kinetic model, it is essential to obtain an arterial input curve, especially if there is no reference region available. Since arterial blood sampling, the gold standard to obtain arterial input curves is very difficult in mice because of the small size and fragility of the mouse blood arteries; an alternative method to acquire the arterial plasma input curve for the kinetic model is proposed.



Male P-gp knock-out (KO) (Mdr1a (-/-)) mice were purchased from Taconic (Hudson, NY, USA) and male wild-type (WT) mice (FVB) were purchased from Charles River Laboratories (Brussels, Belgium) or Elevage Janvier (Le Genest Saint Isle, France). The study was approved by the Ghent University local ethical committee, and all procedures were performed in accordance with the regulations of the Belgian law. All mice had access to food and water ad libitum before the start of the study.

During the entire scan procedure, the animals were kept under anesthesia with 1.5% isoflurane (Medini N.V., Oostkamp, Belgium) administered through a mask and were placed on a heating pad (37°C).


The synthesis of 11C-dLop was performed by the methylation of the precursor didesmethylloperamide with 11C-iodomethane (Figure 1) as reported earlier by our institution [8]. Didesmethylloperamide was kindly provided by Janssen Pharmaceutica (Beerse, Belgium), while tetrabutylammoniumhydroxide, N,N-dimethylformamide and dimethylsulfoxide were purchased from Sigma-Aldrich (Bornem, Belgium).
Figure 1

Radiosynthesis of 11 C-desmethylloperamide. Didesmethylloperamide is methylated with 11CH3I to obtain 11C-desmethylloperamide in the presence of tetrabutylammoniumhydroxide, dimethylsulfoxide, and dimethylformamide.

Comparison of 11C-dLop left heart ventricle time-activity curve and blood counter measurement time-activity curve

WT mice (n = 3) were anesthetized with isoflurane (1.5%) and cannulated with a polyethylene catheter (60 cm, PE10), filled with heparinised saline (0.9%). One end of the catheter was inserted in the carotid artery of the mice by a precise operation, and at the other end, a syringe needle was inserted. The animals were fixed on the μPET scanner, the catheter was inserted inside the detector and the withdrawing syringe was placed on the main pumping unit as described by Convert et al. [9]. Both the μPET scanner (LabPet8; resolution, 1.5 mm) and microvolumetric blood counter (Gamma Medica-Ideas, Quebec, Canada) acquisitions were started in synchronization and subsequent 20-MBq 11C-dLop, dissolved in 100 to 150 μl saline/ethanol mixture (9/1, v/v) was injected intravenously (i.v.). Blood was collected at a constant rate of 10 μl/min for the entire 30-min acquisition time, and the blood time-activity curve was displayed in real time by the software of the microvolumetric blood counter. Immediately after the end of the 11C-dLop scan, the mice were injected with 18.5 MBq of 18F-FDG in a tail vein. Twenty minutes after 18F-FDG injection, a static μPET scan was started for 20 min.

Dynamic 11C-dLop PET data were sorted into frame sequences of 5 s (n = 12), 10 s (n = 6), 1 min (n = 4), 2 min (n = 2), 5 min (n = 2), 10 min (n = 1). A region of interest (ROI) was drawn manually around the left ventricle of the heart (Figure 2A) on the 18F-FDG scan images. Since the position of the mice was unaffected between the 11C-dLop and the 18F-FDG scan, the ROI of the left heart ventricle on the 18F-FDG scan could be pasted on the 11C-scan images (Figure 2B) to derive an arterial blood input function. Data from the blood counter were corrected for dispersion with the following formula: C a(t) = g(t) + τ disp × (dg/dt), where C a(t) is the real whole blood activity curve in mice, g(t) the measured data and dg/dt the derivative of g. τ disp, the dispersion factor was calculated according to Convert et al. [9].
Figure 2

Transversal image of the mice after injection with 11 C-desmethylloperamide and 18 F-FDG. The ROI delineates the left heart ventricle on the (A) 18F-scan and (B) 11C-scan images (color scale: black, lowest radioactivity uptake; red, highest radioactivity uptake).

The estimated input function (18F-FDG-derived) and the measured input function (blood counter) were compared by a direct and indirect method. The direct method, as described by Fang and Muzic [10], evaluated the input functions by calculating the area under the curve (AUC) difference. Indirect comparison examined the impact of the estimated 18F-FDG-derived input function on an estimated kinetic parameter from the kinetic model, like the K 1/k 2 ratio, as described later on (see PET data analysis and kinetic modeling of 11C-dLop). The AUC difference was calculated as absolute values of (AUCPET - AUCbloodcounter)/AUCbloodcounter × 100 and the error percentage of K 1/k 2 ratio as absolute values of (K 1/k 2PET - K 1/k 2bloodcounter)/(K 1/k 2bloodcounter) × 100.

Kinetic model for 11C-dLop

PET experiments

Before positioning the anesthetized mice on the scanner, WT mice (n = 3) were injected i.v. 30 min before the tracer injection with saline (100 μl, controls, n = 3) or 50 mg cyclosporine/kilogram body weight (n = 3) (Novartis, Vilvoorde, Belgium). Approximately 20 MBq of 11C-dLop, dissolved in 100 to 250 μl saline/ethanol mixture (9/1, v/v) was administered via a tail vein, and the dynamic μPET scan was initiated. After the 11C-dLop scan, the mice were injected with approximately 18.5 MBq of 18F-FDG in a tail vein (100 μl). Twenty minutes after the 18F-FDG injection, a static μPET scan was started for 20 min. KO mice (n = 3) were handled in the same way as the WT mice, with exception of the pretreatment procedure.

Determination of percent parent compound in plasma and plasma-whole blood ratio of 11C-dLop

The determination of percent parent compound (11C-dLop) in plasma over time was performed in WT (pretreated with saline or 50 mg cyclosporine/kilogram body weight, n = 3 per group and per time point) and KO mice (n = 3 per time point) using a high-performance liquid chromatography (HPLC) assay. Thirty minutes after pretreatment, the mice were injected with 22.2 to 30 MBq of 11C-dLop (300 μl) and were killed at 1, 10, and 30 min postinjection (p.i.). Blood was collected by cardiac puncture, and the brain was excised. Plasma (200 μl) was obtained after centrifugation (3,000 g, 6 min). Subsequently, 800 μl and 1 ml of acetonitrile (Chem-Lab N.V., Zedelgem, Belgium) were added to the brain and plasma, respectively. Both samples were vortexed (1 min), centrifuged (3,000 g, 3 min), and counted for radioactivity. A supernatant was isolated and analyzed with an HPLC system (Grace Econosphere C18, 10 μm, 10 × 250 mm, eluted with acetonitrile/20 mM sodium acetate (70/30, v/v) as mobile phase at 7 ml/min). Elution fractions of 30 s were collected and counted for radioactivity. Percent parent compound was calculated as the sum of the counts determined in the fractions containing 11C-desmethylloperamide (determined by co-injection with cold desmethylloperamide and UV detection at 220 nm) divided by the total counts of all collected fractions.

To determine the plasma-whole blood ratio, the mice (n = 3) were injected with 4.80 to 5.55 MBq of 11C-dLop (300 μl) and were killed at 0.5, 1, 2, 3, 5, and 10 min p.i.. Blood was collected from the heart by cardiac puncture, counted for radioactivity, and centrifuged for 10 min (3,000 g). Plasma and blood pellet were separated, weighted, and counted for radioactivity. To obtain the plasma-to-whole blood ratio, counts from plasma and blood pellet were averaged for weight.

PET data analysis and kinetic modeling of 11C-dLop

Dynamic 11C-dLop PET data were sorted into frame sequences as mentioned above. The arterial blood input curve obtained from the μPET was corrected for plasma-whole blood ratio and metabolites. An ROI was signed around the whole brain on the 18F-FDG scan images and was used to determine the 11C-dLop brain time-activity curve (Figure 3). All data were loaded and analyzed with the PMOD software package (version 3.1., PMOD Technologies Ltd., Zurich, Switzerland).
Figure 3

An overview of the proposed method to determine a kinetic model of 11 C-desmethylloperamide in mice. A 18F-FDG static μPET scan is used to obtain the input function and the brain time-activity curve by drawing an ROI around the left heart ventricle and the brain.

Standardized uptake values (SUVs) were calculated using the following equation: A/(ID/BW), where A is the decay-corrected radioactivity concentration in the brain (measured in kilobecquerels per cubic centimeter), ID is the injected dose of 11C-dLop (measured in kilobecquerels), and BW is the mice body weight (measured in grams), resulting in SUVs expressed as grams per milliliter. To account for mice differences in the blood concentrations, which are the driving force for the brain concentrations, the brain-to-blood ratio was calculated using the SUVs in the blood and in the brain. A one-tissue compartment model was investigated, in which the rate constants K 1 and k 2 represent, respectively, the rate of transport from plasma to brain and the rate of outflow from the brain to the plasma. A two-tissue compartment model (with or without k4 fixed to 0) was also considered, since interaction of 11C-dLop in the brain might occur. The volume of vasculature was set as a variable in the compartment model.

Statistical analysis

All calculated outcome parameters, differences between WT mice with and without cyclosporine, and KO mice were investigated with ANOVA and Bonferroni post hoc testing. The level of statistical significance was set to 5%.



Based on 11CH3I, 11C-dLop was prepared with a radiochemical yield of 32% (decay-corrected) and with a radiochemical purity of >95%. The specific activity averaged around 70 ± 2 GBq/μmol.

Comparison of 11C-dLop left heart ventricle time-activity curve and blood counter measurement time-activity curve

The data from the blood counter were corrected for dispersion with τ disp calculated as 28 s. A comparison between the left heart ventricle time-activity curves and blood counter dispersion corrected time-activity curves showed acceptable agreement by graphical inspection (Figure 4). The AUC difference was 3.5% ± 4.2%, and the error percentage of the K 1/k 2 ratio was 6.5% ± 3.2%.
Figure 4

Comparison of standard and new 11 C-desmethylloperamide TAC. Comparison of 11C-desmethylloperamide left heart ventricle time-activity curve (TAC) and blood counter dispersion corrected time-activity curve in a mouse.

Kinetic model for 11C-dLop

Determination of percent parent compound in plasma and plasma-whole blood ratio of 11C-dLop

The percent parent compound 11C-dLop at different time points p.i. in mice are summarized in Table 1. Statistical differences were observed either between WT and KO (P < 0.001) and between saline and cyclosporine pretreated WT mice (P < 0.001).
Table 1

Percentage of the parent compound (11C-dLop) in plasma

Mouse strain and pretreatment

% 11 C-desmethylloperamide in plasma


1 min p.i.

10 min p.i.

30 min p.i.

WT, saline

95 ± 1

72 ± 5

53 ± 3

WT, 50 mg cyclosporine/kg

95 ± 1

54 ± 5

23 ± 9


98 ± 1

51 ± 1

34 ± 9

Percentage of the parent compound (11C-dLop) in plasma at 1, 10, and 30 min p.i. in different mouse strains and after different pretreatments. Results are expressed as percent of total radioactivity ± standard deviation. WT, wild-type mice; KO, knock-out mice.

Within the first half minute after 11C-dLop injection, the average ratio of tracer (11C-dLop and 11C-metabolites) plasma concentration to tracer (11C-dLop and 11C-metabolites) whole blood concentration was 0.67 ± 0.04. At 1 min after the tracer injection, the value dropped slightly to 0.49 ± 0.06, while at 3 min the ratio was restabilized to 0.67 ± 0.07. A mean ratio for all time points (0.64 ± 0.09) was further used as correction factor between blood and plasma.

PET data analysis and kinetic modeling of 11C-dLop

Differences in brain uptake of 11C-dLop were clearly observed (Figure 5). The brain SUVs calculated for KO, WT, and WT mice pretreated with cyclosporine were displayed in Figure 6A. In wild-type mice without pretreatment of cyclosporine, the average brain SUVs were 0.250, while in pretreated and KO mice SUVs were significantly higher (0.693 and 0.526, respectively). Although cyclosporine pretreatment of wild-type mice showed higher SUVs in the brain compared to knock-out mice, no statistical difference was observed (P > 0.05), probably due to larger standard deviations in knock-out mice. To exclude variation for the blood concentration over time between the different mice strains, SUVs were determined in the left heart ventricle. No statistical differences in the left heart ventricle SUVs (Figure 6B) were obtained. The brain-to-plasma SUVs are significant different between wild-type mice and KO mice and cyclosporine pretreated wild-type mice (Figure 6C).
Figure 5

Sagittal images of mice after intravenous administration of 11 C-dLop. Sagittal images of knock-out mice (A), wild-type mice without cyclosporine pretreatment (B) and wild-type mice with cyclosporine pretreatment (50 mg/kg body weight, 30 min before tracer injection) (C), after intravenous administration of 20.0 ± 2.0 MBq of 11C-dLop. In each mice, the brains are indicated; the difference in tracer brain uptake between wild-type (no pretreatment), knock-out, and with cyclosporine-pretreated wild-type mice is clearly visible (color scale: black, lowest radioactivity uptake; red, highest radioactivity uptake).

Figure 6

Standard uptake values of 11 C-desmethylloperamide. SUVs of 11C-desmethylloperamide in wild-type mice with saline (1) or 50 mg/kg cyclosporine (2) pretreatment and in knock-out mice (3), expressed in grams per milliliter in function of time in brain (A) and in the left heart ventricle (LV) (B). The ratio of SUVbrain/SUVLV is depicted in graph (C).

The two-tissue compartment model (with or without k4 fixed to 0) did not provide a significantly better fit than the one-tissue compartment model (Figure 7) (Akaike criterion values were in the same range). Moreover, the two-tissue compartment model estimated the kinetic parameters K 1 and k 2 with poorer identifiability than the one-tissue compartment model based on percent covariance values. Hence, Table 2 provides a summary of parameters estimated from the one-tissue compartment model with the noninvasive (left heart ventricle-based) method used to determine the input curve. K 1 in WT mice is statistically smaller than K 1 in knock-out mice (P = 0.008) and in cyclosporine-pretreated mice (P = 0.025), while the k 2 is in the same range in all mice (P > 0.050). The differences between WT and knock-out mice or between saline and cyclosporine pretreatment in WT mice are also reflected in the K 1/k 2 ratio (P = 0.001).
Figure 7

One- and two-compartment model fittings for mice ( n = 3), which were injected with 11 C-dLop. Circles represent observed μPET data taken from a region of interest drawn on the brain.

Table 2

Summary of kinetic parameters


K 1 (ml/cc/min)

k 2 (1/min)

K 1 /k 2

WT 1




WT 2




WT 3




KO 1




KO 2




KO 3
















Summary of kinetic parameters estimated from the one-tissue compartment model for 11C-desmethylloperamide for all mice studied, using the noninvasive (left heart ventricle-based) method to determine the input curve. CYCLO, wild-type mice pretreated with 50 mg/kg cyclosporine, 30 min before tracer injection; KO, knock-out mice; WT, wild-type mice.


Biochemical process steps of a tracer in a tissue can be described by an appropriate tracer kinetic model. The behavior of a tracer is usually simplified and described by some mathematical kinetic compartments [11]. This model should be able to estimate the amount of radioactivity in each compartment, and the rate of exchange between these compartments. In PET imaging, these rate constants directly provide information on physiological parameters characterizing the behavior of the tracer in the tissue of interest. In case there is no reference region available, an arterial input curve is necessary to set up a kinetic model. Manual or automatic blood sampling is generally accepted as the gold standard to determine the arterial input curve. Nevertheless, in mice arterial sampling is technically difficult because of the relatively small diameters and fragility of the mouse blood arteries [12]. In addition, the total blood volume of a mouse is very limited (1.7 ml), making repeated blood sampling impossible without affecting the homeostasis of the mice [13]. Alternative methods to obtain an arterial input function are the use of a population database, based on a high number of mice or an arterial input function derived from PET images [14]. Attempts to determine the arterial input function in small animals from PET images were not convincing. Difficult delineation of the left heart ventricle on the PET scan in mice [15] or background signals from surrounding tissues in rats [16] were the main problems. Due to blurred 11C-dLop images on early as well as late time frames, it was impossible to delineate the left heart ventricle accurately. We therefore propose a new image-derived method, using a 18F-FDG scan after a 11C-dLop scan. Unlike 11C-dLop, 18F-FDG shows a selective uptake in the myocardium [1719], making the determination of the left ventricle easy without the problem of spill-in of activity from the surrounding lungs. A comparison between the left heart ventricle time-activity curves (alternative method) and blood counter time-activity curves (corrected for dispersion) showed acceptable graphical agreement. A small AUC difference (3.5%) was observed compared to Green et al. (18%) [20], who did not use a 18F-FDG scan to delineate the left heart ventricle, but instead a small ROI based on the highest activity in the aorta area on the earliest time frames. Also, the comparison of the K 1/k 2 ratio showed analog correlations (6.5%) between standard blood sampling and our proposed method. However, one must realize that the usefulness of our method must be validated for each radioligand because determination of the arterial input function based on the left ventricle could lead to a poor resemblance with the blood sampling input curve especially for radioligands with high myocardial uptake.

Both in wild-type and in P-gp knock-out mice, the percent of parent compound was investigated, resulting in variations probably due to the influence of cyclosporine or to an adaptation of the body to the absence of P-gp efflux transporters. These differences are not an obstacle concerning our experiment because the latter correction was introduced to take these differences into consideration.

Variations in 11C-dLop brain uptake between wild-type and knock-out/cyclosporine-pretreated mice were clearly observed in μPET images and SUVs. Moreover, differences in 11C-dLop uptake in the intestines were observed and could be explained by the absence of P-gp in KO mice resulting in a lower tracer uptake, while in WT mice P-gp located in the intestines pumps the tracer out of the blood into the intestines, resulting in higher uptake. The higher radioactivity in the abdomen of WT mice, as observed in Figure 5, could also be explained as higher uptake in the liver, which is in accordance with results obtained in humans [21]. Nevertheless, kinetic parameters obtained from a compartment model will provide useful mathematical information about the behavior of the tracer. Since no statistical difference in model fittings between the one- and two-compartment model was observed, the simplest model, meaning the one-tissue compartment model, was preferred. This is in accordance to the results mentioned by Kreisl et al. [22]. In a one-tissue compartment model, the tracer behaves in a straightforward manner explained by an uptake in the brain with a speed, represented by the kinetic parameter K 1, and efflux out of the brain described by k 2. Binding with any receptors in the brain or metabolisation of the tracer in the brain will not occur in this model. Lazarova et al. [6] already mentioned that 11C-dLop showed no clinical relevant interaction with the opiate receptors in the brain.

The kinetic parameters K 1 and k 2 obtained from a one-tissue compartment model of 11C-dLop were evaluated in WT, KO, and WT mice pretreated with cyclosporine. One should expect that K 1, which represents the passive influx of the tracer in the brain, should not change between the different groups. k 2, which represents the efflux out of the brain by P-gp transport, was supposed to be lower in KO mice and in the WT mice pretreated with cyclosporine. Our data showed that the K 1 was statistically lower in WT mice compared to KO or cyclosporine-pretreated WT mice, while the k 2 was very similar in all tested mice. Kreisl et al. [22] reported the same result after blockage of the P-gp with tariquidar and suggested that tariquidar increased brain uptake of 11C-dLop by increasing its entry (K 1) rather than by decreasing its efflux (k 2). The substrate is captured in the endothelial cells, before it enters the intracellular compartment. Therefore, if P-gp captures all of the substrate while in transit through the membrane, its effect is entirely on K 1. If some of the substrate escapes and has time to interact with the intracellular milieu, and if there is an efflux from the cell, P-gp will both decrease K 1 and increase k 2 [23]. Nevertheless, we think that also a time influence of the P-gp transport should be taken into consideration. The course of the brain SUV curve (Figure 6A) in WT mice demonstrates a fast uptake in the brain, followed by a rapid wash out of the brain, resulting in an SUV of 0.25 already 1 min after the tracer injection, while in KO and pretreated WT mice also a fast uptake was observed, followed by an accumulation in the brain of the tracer combined with a slow efflux. The observed different course of the brain curve between WT and KO mice, even as between cyclosporine pretreated WT mice suggests that the duration of the scan could play an important role on the determination of the kinetic parameters in the kinetic model.

This hypothesis was substantiated by the results of K 1 and k 2 obtained in a one-tissue compartment model with incorporation of only the first 2 min of dynamic scanning. These results showed a statistically higher k 2 in WT mice (8.0 ± 0.1) compared to KO (2.3 ± 0.9; P = 0.070) and compared to cyclosporine pretreated WT mice (1.5 ± 0.5; P = 0.002), while K 1 was statistically not different between the different groups (P > 0.05). This means that during the first 2 min after administration of 11C-dLop, efflux out of the brain is dominated by efflux transporters, while at later time points passive diffusion is more important. The K 1/k 2 ratio of WT obtained with the 2-min scan data were statistically different compared to the ratios in KO and compared to cyclosporine-pretreated WT mice. So, we propose K 1 as a pseudo value, representing a combination of passive influx of 11C-dLop through the BBB and a rapid energy dependent output by P-gp, while k 2 corresponds to slow passive efflux out of the brain (Figure 8).
Figure 8

Schematic representation of different methods to determine the rate constants obtained from one-tissue compartment model. (A) Rate constants K 1 and k 2, obtained from one-tissue compartment model with all scan data incorporated. K 1 represents the passive influx, while k 2 is a combination of active and passive efflux. (B) shows rate constants obtained from a one-tissue compartment model with only the first 2 min of the scan data. Pseudo K 1 is defined as a combination of the passive influx and active efflux, but k 2 only represents passive efflux. C, concentration of 11C-dLop.


The use of an easy to implement 11C-desmethylloperamide kinetic model in mice for imaging P-gp function is presented without arterial blood sampling. The method to determine the input function is based on the delineation of an ROI on the 18F-FDG scan images and using this ROI on images obtained from a dynamic scan with 11C-dLop. The K 1 or K 1/k 2 ratio obtained from the 11C-dLop tracer kinetic model is a good parameter for the active P-gp rate and can be applied in future experiments to evaluate the role of the upregulation of P-gp in psychotropic drug resistance, such as refractory epilepsy and in tumor resistance to therapy.



antiepileptic drugs


area under the curve


blood-brain barrier


mice body weight








injected dose




P-glycoprotein knock-out mice




post injection


standardized uptake values




wild-type mice.



We are grateful to the cyclotron team for their support during the synthesis of the tracer. We would like to thank Philippe Joye for the animal manipulation before and during the scans and Steven Deleye for the reconstructions of the scans. Janssen Pharmaceutica is acknowledged for the donation of desmethylloperamide and didesmethylloperamide. We also like to thank FWO-Vlaanderen for funding and Prof. Pascal Verdonck for the scientific support.

Authors’ Affiliations

Laboratory of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University
Department of Civil Engineering, Institute Biomedical Technology, Ghent University
Laboratory for Clinical and Experimental Neurophysiology (LCEN), Department of Neurology, Ghent University Hospital


  1. Löscher W, Potschka H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002, 301: 7–14. 10.1124/jpet.301.1.7PubMedView ArticleGoogle Scholar
  2. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125: 22–31. 10.1093/brain/awf002PubMedView ArticleGoogle Scholar
  3. Marchi NM, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, Dini G, Vezzani A, Janigro D: Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004, 2: 1–10. 10.1186/1741-7015-2-1View ArticleGoogle Scholar
  4. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annette GM, Raffel C: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36: 1–6.PubMedView ArticleGoogle Scholar
  5. Sadeque AJM, Wandel C, He HB, Shah S, Wood AJJ: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000, 68: 231–237. 10.1067/mcp.2000.109156PubMedView ArticleGoogle Scholar
  6. Lazarova N, Zoghbi SS, Hong J, Seneca N, Tuan E, Gladding RL, Liow JS, Taku A, Innis RB, Pike VW: Synthesis and evaluation of (N-methyl-11C)N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 2008, 51: 6034–6043. 10.1021/jm800510mPubMed CentralPubMedView ArticleGoogle Scholar
  7. Zhang Y, Bachmeier C, Miller DW: In vitro and in vivo models for assessing drug efflux transporter activity. Adv Drug Deliver Rev 2003, 55: 31–51. 10.1016/S0169-409X(02)00170-9View ArticleGoogle Scholar
  8. Moerman L, Wyffels L, Slaets D, Raedt R, Boon P, De Vos F: Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with 11 C-desmethylloperamide. Epilepsy Res 2011, 94: 18–25. 10.1016/j.eplepsyres.2010.12.013PubMedView ArticleGoogle Scholar
  9. Convert L, Morin-Brassard G, Cadorette J, Archambault M, Bentourkia M, Lecomte R: A new tool for molecular imaging: the microvolumetric β blood counter. J Nucl Med 2007, 48: 1197–1206. 10.2967/jnumed.107.042606PubMedView ArticleGoogle Scholar
  10. Fang YD, Muzic RF: Spillover and partial-volume correction for image-derived input functions for small-animal 18 F-FDG PET studies. J Nucl Med 2008, 49: 606–614. 10.2967/jnumed.107.047613PubMedView ArticleGoogle Scholar
  11. Carson RE: Tracer Kinetic modeling in PET. In Positron emission tomography: Basic Science and clinical practice. Volume 1. 1st edition. Edited by: Valk PE, Bailey DL, Townsend DW, Maisey MN. London: Springer; 2003:147–179.Google Scholar
  12. Green LA, Gambhir SS, Srinivasan A, Banerjee PK, Hoh CK, Cherry SR, Sharfstein S, Barrio JR, Herschman HR, Phelps ME: Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med 1998, 39: 729–734.PubMedGoogle Scholar
  13. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993, 10: 1093–1095. 10.1023/A:1018943613122PubMedView ArticleGoogle Scholar
  14. Bentourkia M, Zaidi H: Tracer kinetic modeling in nuclear medicine: Theory and application. In Quantitative analysis in nuclear medicine imaging. Volume 1. 1st edition. Edited by: Zaidi H. New York: Springer; 2006:391–414.View ArticleGoogle Scholar
  15. Choi SJ, Kim SY, Kim SJ, Lee JS, Lee SJ, Park SA, Lee SJ, Yun SC, Im KC, Oh SJ, Kim SW, Kim JS, Ryu JS, Moon DH: Reproducibility of the kinetic analysis of 3'-deoxy-3'( 18 F)fluorothymidine positron emission tomography in mouse tumor models. Nucl Med Biol 2009, 36: 711–719. 10.1016/j.nucmedbio.2009.06.001PubMedView ArticleGoogle Scholar
  16. Pain F, Lanièce P, Mastrippolito R, Gervais P, Hantraye P, Besret L: Arterial input function measurement without blood sampling using a β-microprobe in rats. J Nucl Med 2004, 45: 1577–1582.PubMedGoogle Scholar
  17. Phelps ME, Hoffman ED, Selin C, Huang SC, Robinson G, MacDonald N, Schelbert H, Kuhl DE: Investigation of (18F)2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med 1978, 19: 1311–1319.PubMedGoogle Scholar
  18. Landoni C, Bettinardi V, Lucignani G, Gilardi MC, Striano S, Fazio F: A procedure for wall detection in ( 18 F)FDG positron emission tomography heart studies. Eur J Nucl Med 1996, 23: 18–24. 10.1007/BF01736985PubMedView ArticleGoogle Scholar
  19. Kim J, Herrero P, Sharp T, Laforest R, Rowland DJ, Tai YC, Lewis JS, Welch MJ: Minimally invasive method of determining blood input function from PET images in rodents. J Nucl Med 2006, 47: 330–336.PubMedGoogle Scholar
  20. Green LA, Nguyen K, Berenji B, Iyer M, Bauer E, Barrio J, Namavari M, Satyamurthy N, Gambhir SS: A tracer kinetic model for 18 F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J Nucl Med 2004, 45: 1560–1570.PubMedGoogle Scholar
  21. Seneca N, Zoghbi SS, Liow JS, Kreisl W, Herscovitch P, Jencko K, Gladding RL, Taku A, Pike VW, Inins RB: Human brain imaging and radiation dosimetry of 11 C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med 2009, 50: 807–813. 10.2967/jnumed.108.058453PubMed CentralPubMedView ArticleGoogle Scholar
  22. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB: P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11 C-N-desmethyl-loperamide. J Nucl Med 2010, 51: 559–566. 10.2967/jnumed.109.070151PubMed CentralPubMedView ArticleGoogle Scholar
  23. Kannan P, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD: Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009, 86: 368–377. 10.1038/clpt.2009.138PubMed CentralPubMedView ArticleGoogle Scholar


© Moerman et al; licensee Springer. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.